Continued Momentum Lifted Adaptive Biotechnologies Corporation (ADPT) in Q3

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” third-quarter 2025 investor letter. The letter highlighted the market review, quarterly performance, and attribution analysis. A copy of the letter can be downloaded here. In the quarter, the US equity market rallied, with the S&P 500 Index reaching 8.12%. Bonds also finished higher in the period, with the Bloomberg U.S. Aggregate Bond Index increasing 2.03%. The composite has returned 7.22% gross of fees (7.10% net of fees) in the quarter, underperforming the S&P 500 Index’s 8.12% gain. Security selection led to the relative underperformance of the strategy in the quarter. In addition, please check the fund’s top five holdings to know its best picks in 2025.

In its third-quarter 2025 investor letter, Aristotle Atlantic Core Equity Strategy highlighted stocks such as Adaptive Biotechnologies Corporation (NASDAQ:ADPT). Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is a commercial-stage biotechnology company. The one-month return of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) was -20.92%, and its shares gained 201.28% of their value over the last 52 weeks. On November 14, 2025, Adaptive Biotechnologies Corporation (NASDAQ:ADPT) stock closed at $14.10 per share, with a market capitalization of $2.159 billion.

Aristotle Atlantic Core Equity Strategy stated the following regarding Adaptive Biotechnologies Corporation (NASDAQ:ADPT) in its third quarter 2025 investor letter:

“Adaptive Biotechnologies Corporation (NASDAQ:ADPT) contributed to performance in the third quarter as momentum continued in its minimal residual disease (MRD) testing business, anchored by its flagship clonoSEQ test for MRD in several hematological cancers. During the quarter, the company reported better-than-expected earnings and raised full-year guidance. Average selling price (ASP) increases are complementing accelerating volume growth.”

Adaptive Biotechnologies Corporation (ADPT): Among Stocks Insiders Are Selling In March

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 26 hedge fund portfolios held Adaptive Biotechnologies Corporation (NASDAQ:ADPT) at the end of the second quarter, compared to 27 in the previous quarter. While we acknowledge the risk and potential of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Adaptive Biotechnologies Corporation (NASDAQ:ADPT) and that has 10,000% upside potential, check out our report about this cheapest AI stock.

In another article, we covered Adaptive Biotechnologies Corporation (NASDAQ:ADPT) and shared the list of must-buy small-cap stocks to invest in. In addition, please check out our hedge fund investor letters Q3 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.